Showing 4981-4990 of 7030 results for "".
- Risk-Guided Screening Enhances Early Skin Cancer ID in Transplant Cohorthttps://practicaldermatology.com/news/risk-guided-screening-enhances-early-skin-cancer-id-in-transplant-cohort/2483972/A risk-based skin cancer surveillance strategy was associated with improved early detection rates among solid organ transplant (SOT) recipients, according to findings from a recent retrospective cohort analysis of the implementation of the KP-SUNTRAC program across K
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseaseshttps://practicaldermatology.com/news/leo-pharma-finalizes-acquisition-of-spevigo-for-rare-dermatologic-diseases/2483600/LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer. The purchase represents the c
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the
- Meta-analysis: Severe Childhood Sunburns Triple Risk of cSCChttps://practicaldermatology.com/news/meta-analysis-severe-childhood-sunburns-triple-risk-of-cscc/2483566/Data from a new meta-analysis showed an association between severe sunburn history and increased risk of cutaneous squamous cell carcinoma (cSCC) across all life stages. Researchers publishing in JAMA Dermatology use
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Analysis: IL-17, JAK Inhibitors May Carry Elevated Risk for TBhttps://practicaldermatology.com/news/analysis-il-17-jak-inhibitors-may-carry-elevated-risk-for-tb/2483387/A large population-based analysis using data from TriNetX suggests a elevated risk of active tuberculosis (TB) in patients treated with systemic immunosuppressive therapies (including IL-17, IL-23, IL-12/23, Janus kinase (JAK) inhibitors), cyclosporine, and tumor ne